Mainz Biomed N.V.
NASDAQ Global MarketTotal Valuation
Mainz Biomed N.V. carries a market capitalization of 17.81M, placing it among publicly traded companies globally. Its enterprise value stands at 349,855.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 17.81M |
| Enterprise Value | 349,855.00 |
Share Statistics
Mainz Biomed N.V. currently has 529,137.00 shares outstanding.
| Shares Outstanding | 529,137.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.39 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Mainz Biomed N.V. maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.97 |
| Quick Ratio | 0.80 |
| Debt / Equity | 228.39 |
| Debt / EBITDA | -0.29 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -147.52 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.98 |
Stock Price Statistics
Mainz Biomed N.V.'s stock has gained approximately 77.9% over the past 52 weeks. The 50-day moving average sits at 0.74, while the 200-day moving average is 0.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | 77.9% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 0.74 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mainz Biomed N.V. generated 895,479.00 in revenue and converted that into -26.30M in net income, yielding earnings per share of -69.24. EBITDA reached -25.99M, while operating income came in at -26.85M.
| Revenue | 895,479.00 |
| Gross Profit | 509,659.00 |
| Operating Income | -26.85M |
| Pretax Income | -26.30M |
| Net Income | -26.30M |
| EBITDA | -25.99M |
| EBIT | -26.85M |
| Earnings Per Share (EPS) | -69.24 |
Balance Sheet
Mainz Biomed N.V. holds 7.07M in cash and equivalents against 7.42M in total debt, resulting in a net debt position of -1.10M. Total book value stands at -69.09M, with working capital of -257,040.00 providing operational flexibility.
| Cash & Cash Equivalents | 7.07M |
| Total Debt | 7.42M |
| Net Debt | -1.10M |
| Equity (Book Value) | -69.09M |
| Book Value Per Share | -181.93 |
| Working Capital | -257,040.00 |
Cash Flow
Mainz Biomed N.V. produced -21.94M in operating cash flow over the past twelve months. After subtracting -1.90M in capital expenditures, free cash flow totaled -23.84M - equivalent to -62.77 per share.
| Operating Cash Flow | -21.94M |
| Capital Expenditures | -1.90M |
| Free Cash Flow | -23.84M |
| FCF Per Share | -62.77 |
Margins
Mainz Biomed N.V. operates with a gross margin of 56.91, reflecting its pricing power and cost economics. The operating margin of -2,998.88 and net profit margin of -2,936.50 provide insight into operational efficiency.
| Gross Margin | 56.91 |
| Operating Margin | -2,998.88 |
| Pretax Margin | -2,936.50 |
| Profit Margin | -2,936.50 |
| EBITDA Margin | -2,902.12 |
Scores
Mainz Biomed N.V. posts an Altman Z-Score of -15.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.41 |